home / stock / snoa / snoa news

SNOA News and Press, Sonoma Pharmaceuticals Inc. From 03/30/22

Stock Information
Company Name: Sonoma Pharmaceuticals Inc.
Stock Symbol: SNOA
Market: NASDAQ
Website: sonomapharma.com
Menu
SNOA SNOA Quote SNOA Short SNOA News SNOA Articles SNOA Message Board
Get SNOA Alerts

News, Short Squeeze, Breakout and More Instantly...
SNOA - Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditio...
SNOA - Sonoma Pharmaceuticals GAAP EPS of -$0.31, revenue of $2.9M

Sonoma Pharmaceuticals press release (NASDAQ:SNOA): FQ3 GAAP EPS of -$0.31. Revenue of $2.9M (-41.3% Y/Y). For further details see: Sonoma Pharmaceuticals GAAP EPS of -$0.31, revenue of $2.9M

SNOA - Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results

Gross Profit Percentage for the Quarter ended December 31, 2021 Increased 1% versus Prior Year and 8% versus Prior Quarter Net loss per Share of $(0.31) for the Third Quarter Compared to a Net Loss per Share of $(0.32) for the Prior Year $8.5 Million of Cash and Stre...

SNOA - Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermat...
SNOA - Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it wi...

SNOA - Sonoma Pharmaceuticals reports Q2 results

Sonoma Pharmaceuticals (NASDAQ:SNOA): Q2 GAAP EPS of -$0.04. Revenue of $3.74M (-35.2% Y/Y) Press Release For further details see: Sonoma Pharmaceuticals reports Q2 results

SNOA - Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results

Revenues hold steady from prior quarter ended June 30, 2021 Net loss of $100,000, or $(0.04) per share for the second quarter compared to a net loss of $1.1 million or $(0.52) per share for the prior quarter ended June 30, 2021 Break-even EBITDAS for the quarter vers...
SNOA - Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its ...

SNOA - Jasper Therapeutics, 23andMe leads healthcare gainers; Grove, Myomo among major losers

Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...

SNOA - Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its ...
Previous 10 Next 10